[1]舒画,杨迎,李新,等.从糖尿病分型的演变看单基因糖尿病个体化精准诊疗及其科研价值[J].国际内分泌代谢杂志,2021,41(05):413-417.[doi:10.3760/cma.j.cn121383-20210915-09041]
　Shu Hua,Yang Ying,Li Xin,et al.The lesson from evolution of diabetes classification to individualized precision medicine of monogenic diabetes[J].International Journal of Endocrinology and Metabolism,2021,41(05):413-417.[doi:10.3760/cma.j.cn121383-20210915-09041]
点击复制

从糖尿病分型的演变看单基因糖尿病个体化精准诊疗及其科研价值()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年05期
页码:
413-417
栏目:
述评
出版日期:
2021-09-30

文章信息/Info

Title:
The lesson from evolution of diabetes classification to individualized precision medicine of monogenic diabetes
作者:
舒画; 杨迎; 李新; 刘铭
天津医科大学总医院内分泌代谢科 300050
Author(s):
Shu Hua;  Yang Ying;  Li Xin;  Liu Ming.
Department of Endocrinology and Metabolism, the General Hospital of Tianjin Medical University, Tianjin 300050, China
关键词:
糖尿病分型;  单基因糖尿病;  精准医学
Keywords:
Classification of diabetes;  Monogenic diabetes;  Precision medicine
DOI:
10.3760/cma.j.cn121383-20210915-09041
摘要:
糖尿病分型是指导临床决策的重要依据,世界卫生组织(WHO)在1965年首次对糖尿病进行分型,并先后进行了4次更新,这些分型的演变不仅在一定程度上体现了半个多世纪以来对于糖尿病发病机制和临床发展结局认识的深入,同时也更好地应对了临床实际需求,增加了分型的灵活性、可操作性和动态演变性。鉴于糖尿病本身的复杂性和异质性,以及对糖尿病认识的局限性,目前的糖尿病分型还有很多未能满足的临床需求。结合糖尿病的病理生理学基础、临床表型、并发症的易感性、对药物的反应性和基因分子诊断等特征的精准分型,是未来糖尿病分型的发展方向。由单一基因突变所致的单基因糖尿病为糖尿病个体化精准管理提供了一个良好范例。
Abstract:
The classification of diabetes provides an important basis for clinical decision of diabetes management. World Health Organization(WHO)announced the first diabetes classification in 1965, and has updated it four times over the past half century. These updates not only reflected the better understanding of diabetes pathogenesis and clinical outcomes, but also highlighted the importance of clinical needs for the management of diabetes. However, the classification systems are clearly limited by significant knowledge gaps and available resources for diabetes management. Therefore, the most updated WHO classification of diabetes prioritizes clinical care to guide health professionals choose appropriate treatments, particularly at the time of diagnosis. There are significant unmet clinical needs for classification of diabetes. Accumulating evidence indicates that monogenic diabetes appears to be the best clinical model for precise medicine and individualized management of diabetes.

参考文献/References:

[1] Colagiuri S.Definition and classification of diabetes and prediabetes and emerging data on phenotypes[J].Endocrinol Metab Clin North Am,2021,50(3):319-336.DOI:10.1016/j.ecl.2021.06.004.
[2] Ahlqvist E,Storm P,Käräjämäki A,et al.Novel subgroups of adult-onset diabetes and their association with outcomes:a data-driven cluster analysis of six variables[J].Lancet Diabetes Endocrinol,2018,6(5):361-369.DOI:10.1016/S2213-8587(18)30051-2.
[3] Zou X,Zhou X,Zhu Z,et al.Novel subgroups of patients with adult-onset diabetes in Chinese and US populations[J].Lancet Diabetes Endocrinol,2019,7(1):9-11.DOI:10.1016/S2213-8587(18)30316-4.
[4] Shi D,Motamed M,Mejía-Benítez A,et al.Genetic syndromes with diabetes:A systematic review[J].Obes Rev,2021,22(9):e13303.DOI:10.1111/obr.13303.
[5] Wolfsdorf JI,Allgrove J,Craig ME,et al.ISPAD clinical practice consensus guidelines 2014.Diabetic ketoacidosis and hyperglycemic hyperosmolar state[J].Pediatr Diabetes,2014,15 Suppl 20:154-179.DOI:10.1111/pedi.12165.
[6] Carlsson A,Shepherd M,Ellard S,et al.Absence of islet autoantibodies and modestly raised glucose values at diabetes diagnosis should lead to testing for MODY:Lessons from a 5-Year pediatric swedish national cohort study[J].Diabetes Care,2020,43(1):82-89.DOI:10.2337/dc19-0747.
[7] Shepherd M,Shields B,Hammersley S,et al.Systematic population screening,using biomarkers and genetic testing,identifies 2.5% of the U.K.pediatric diabetes population with monogenic diabetes[J].Diabetes Care,2016,39(11):1879-1888.DOI:10.2337/dc16-0645.
[8] Pihoker C,Gilliam LK,Ellard S,et al.Prevalence,characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A,HNF4A,and glucokinase:results from the SEARCH for Diabetes in Youth[J].J Clin Endocrinol Metab,2013,98(10):4055-4062.DOI:10.1210/jc.2013-1279.
[9] Shields BM,Hicks S,Shepherd MH,et al.Maturity-onset diabetes of the young(MODY):how many cases are we missing?[J].Diabetologia,2010,53(12):2504-2508.DOI:10.1007/s00125-010-1799-4.
[10] 黄雨蒙,舒画,刘铭.六种常见单基因糖尿病的临床特征及个体化精准诊疗[J].中华内分泌代谢杂志,2019,39(2):165-170.DOI:10.3760/cma.j.issn.1000-6699.2019.02.015.
[11] Steele AM,Shields BM,Wensley KJ,et al.Prevalence of vascular complications among patients with glucokinase mutations and prolonged,mild hyperglycemia[J].JAMA,2014,311(3):279-286.DOI:10.1001/jama.2013.283980.
[12] Udler MS,Powe CE,Austin-Tse CA.Case 6-2020:a 34-year-old woman with hyperglycemia[J].N Engl J Med,2020,382(8):745-753.DOI:10.1056/NEJMcpc1913475.
[13] Pearson ER,Flechtner I,Njølstad PR,et al.Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations[J].N Engl J Med,2006,355(5):467-477.DOI:10.1056/NEJMoa061759.
[14] Bowman P,Sulen Å,Barbetti F,et al.Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations:an international cohort study[J].Lancet Diabetes Endocrinol,2018,6(8):637-646.DOI:10.1016/S2213-8587(18)30106-2.
[15] Beltrand J,Elie C,Busiah K,et al.Sulfonylurea therapy benefits neurological and psychomotor functions in patients with neonatal diabetes owing to potassium channel mutations[J].Diabetes Care,2015,38(11):2033-2041.DOI:10.2337/dc15-0837.
[16] Liu M,Sun J,Cui J,et al.INS-gene mutations:from genetics and beta cell biology to clinical disease[J].Mol Aspects Med,2015,42:3-18.DOI:10.1016/j.mam.2014.12.001.
[17] Liu M,Hodish I,Haataja L,et al.Proinsulin misfolding and diabetes:mutant INS gene-induced diabetes of youth[J].Trends Endocrinol Metab,2010,21(11):652-659.DOI:10.1016/j.tem.2010.07.001.
[18] Ank A,Çatl G,Abac A,et al.Maturity-onset diabetes of the young(MODY):an update[J].J Pediatr Endocrinol Metab,2015,28(3-4):251-263.DOI:10.1515/jpem-2014-0384.
[19] Njølstad PR,Molven A.To test,or not to test:time for a MODY calculator?[J].Diabetologia,2012,55(5):1231-1234.DOI:10.1007/s00125-012-2514-4.
[20] Liang H,Zhang Y,Li M,et al.Recognition of maturity-onset diabetes of the young in China[J].J Diabetes Investig,2021,12(4):501-509.DOI:10.1111/jdi.13378.
[21] 郑泰山,杨震,吴松华,等.中国人早发及多发糖尿病人群中葡萄糖激酶基因筛查及1个新的错义突变V5L的发现[J].中国糖尿病杂志,2010,18(9):660-664.DOI:10.3969/j.issn.1006-6187.2010.09.006.

相似文献/References:

[1]何丽 李蓉.单基因糖尿病的精准医疗[J].国际内分泌代谢杂志,2018,38(03):188.[doi:10.3760/cma.j.issn.1673-4157.2018.03.011]
　He Li,Li Rong..Precision medicine of monogenic diabetes[J].International Journal of Endocrinology and Metabolism,2018,38(05):188.[doi:10.3760/cma.j.issn.1673-4157.2018.03.011]
[2]欧杨,周怡昆.青少年发病的成人型糖尿病的妊娠期管理[J].国际内分泌代谢杂志,2021,41(05):422.[doi:10.3760/cma.j.cn121383-20210622-06062]
　Ou Yang,Zhou Yikun..Gestational management of maturity-onset diabetes of the young[J].International Journal of Endocrinology and Metabolism,2021,41(05):422.[doi:10.3760/cma.j.cn121383-20210622-06062]

备注/Memo

备注/Memo:
基金项目:天津市科技计划项目(2020KJ47)
通信作者:刘铭,Email:mingliu@tmu.edu.cn 舒画和杨迎为共同第一作者
更新日期/Last Update: 2021-10-10